Immunotherapy expands and maintains the function of high-affinity tumor-infiltrating CD8 T cells in situ

Journal of Immunology

Volumn 197, Issue 6, 2016, Pages 2509-2521

  Moran, Amy E ^a   Polesso, Fanny ^a   Weinberg, Andrew D ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CD69 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; HERMES ANTIGEN; INTERFERON; INTERLEUKIN 10; MONOCLONAL ANTIBODY; NUCLEAR RECEPTOR NUR77; OX40 MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; CTLA4 PROTEIN, MOUSE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIGEN RECEPTOR; NR4A1 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; TNFRSF4 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; FEMALE; IN SITU HYBRIDIZATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; SIGNAL TRANSDUCTION; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; UPREGULATION; AGONISTS; ANIMAL; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OX40; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84988978556     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502659     Document Type: Article

References (63)

1. Zehn, D., S. Y. Lee, and M. J. Bevan. 2009. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458: 211-214.
2. Schumacher, T. N., and R. D. Schreiber. 2015. Neoantigens in cancer immunotherapy. Science 348: 69-74.
3. Gubin, M.M., X. Zhang, H. Schuster, E.Caron, J. P.Ward, T. Noguchi, Y. Ivanova, J. Hundal, C. D. Arthur, W. J. Krebber, et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515: 577-581.
4. Kreiter, S., M. Vormehr, N. van de Roemer, M. Diken, M. Löwer, J. Diekmann, S. Boegel, B. Schrörs, F. Vascotto, J. C. Castle, et al. 2015. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520: 692-696.
5. Coulie, P. G., F. Lehmann, B. Lethé, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci. USA 92: 7976-7980.
6. Wölfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wölfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Büschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284.
7. Rizvi, N. A., M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, W. Lee, J. Yuan, P. Wong, T. S. Ho, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124-128.
8. Robbins, P. F., Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, J. C. Lin, J. K. Teer, P. Cliften, E. Tycksen, et al. 2013. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19: 747-752.
9. van Rooij, N., M. M. van Buuren, D. Philips, A. Velds, M. Toebes, B. Heemskerk, L. J. van Dijk, S. Behjati, H. Hilkmann, D. El Atmioui, et al. 2013. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31: e439-e442.
10. Tran, E., M. Ahmadzadeh, Y. C. Lu, A. Gros, S. Turcotte, P. F. Robbins, J. J. Gartner, Z. Zheng, Y. F. Li, S. Ray, et al. 2015. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350: 1387-1390.
11. Tran, E., S. Turcotte, A. Gros, P. F. Robbins, Y. C. Lu, M. E. Dudley, J. R. Wunderlich, R. P. Somerville, K. Hogan, C. S. Hinrichs, et al. 2014. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344: 641-645.
12. Zhai, Y., J. C. Yang, P. Spiess, M. I. Nishimura, W. W. Overwijk, B. Roberts, N. P. Restifo, and S. A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20: 15-25.
13. Alexander, R. B., E. B. Fitzgerald, A. Mixon, C. S. Carter, M. Jakobsen, P. A. Cohen, and S. A. Rosenberg. 1995. Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J. Immunother. Emphasis Tumor Immunol. 17: 39-46.
14. Gros, A., P. F. Robbins, X. Yao, Y. F. Li, S. Turcotte, E. Tran, J. R. Wunderlich, A. Mixon, S. Farid, M. E. Dudley, et al. 2014. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124: 2246-2259.
15. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/ pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286.
16. Shiow, L. R., D. B. Rosen, N. Brdicková, Y. Xu, J. An, L. L. Lanier, J. G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540-544.
17. Sun, S., X. Zhang, D. F. Tough, and J. Sprent. 1998. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188: 2335-2342.
18. Godfrey, W. R., F. F. Fagnoni, M. A. Harara, D. Buck, and E. G. Engleman. 1994. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J. Exp. Med. 180: 757-762.
19. Baldwin, T. A., and K. A. Hogquist. 2007. Transcriptional analysis of clonal deletion in vivo. J. Immunol. 179: 837-844.
20. Winoto, A., and D. R. Littman. 2002. Nuclear hormone receptors in T lymphocytes. Cell 109(Suppl.): S57-S66.
21. Zikherman, J., R. Parameswaran, and A. Weiss. 2012. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489: 160-164.
22. Moran, A. E., K. L. Holzapfel, Y. Xing, N. R. Cunningham, J. S. Maltzman, J. Punt, and K. A. Hogquist. 2011. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J. Exp. Med. 208: 1279-1289.
23. Paterson, D. J., W. A. Jefferies, J. R. Green, M. R. Brandon, P. Corthesy, M. Puklavec, and A. F. Williams. 1987. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol. Immunol. 24: 1281-1290.
24. Montler, R., R. B. Bell, C. Thalhofer, R. Leidner, Z. Feng, B. A. Fox, A. C. Cheng, T. G. Bui, C. Tucker, H. Hoen, and A.Weinberg. 2016. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin. Transl. Immunology 5: e70.
25. Weinberg, A. D., M. M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164: 2160-2169.
26. Ruby, C. E., W. L. Redmond, D. Haley, and A. D. Weinberg. 2007. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. Eur. J. Immunol. 37: 157-166.
27. Redmond, W. L., M. J. Gough, and A. D. Weinberg. 2009. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur. J. Immunol. 39: 2184-2194.
28. Curti, B. D., M. Kovacsovics-Bankowski, N. Morris, E. Walker, L. Chisholm, K. Floyd, J. Walker, I. Gonzalez, T. Meeuwsen, B. A. Fox, et al. 2013. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73: 7189-7198.
29. Lees, J. R., B. Charbonneau, A. K. Swanson, R. Jensen, J. Zhang, R. Matusik, and T. L. Ratliff. 2006. Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology 117: 248-261.
30. Mackay, L. K., A. Braun, B. L. Macleod, N. Collins, C. Tebartz, S. Bedoui, F. R. Carbone, and T. Gebhardt. 2015. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J. Immunol. 194: 2059-2063.
31. Liu, F., and J. L. Whitton. 2005. Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections. J. Immunol. 174: 5936-5940.
32. Balkwill, F., and A. Mantovani. 2001. Inflammation and cancer: back to Virchow? Lancet 357: 539-545.
33. Coussens, L. M., and Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867.
34. Lanier, L. L., D. W. Buck, L. Rhodes, A. Ding, E. Evans, C. Barney, and J. H. Phillips. 1988. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J. Exp. Med. 167: 1572-1585.
35. Oppenheimer-Marks, N., L. S. Davis, and P. E. Lipsky. 1990. Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell. J. Immunol. 145: 140-148.
36. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
37. Fasso, M., R. Waitz, Y. Hou, T. Rim, N. M. Greenberg, N. Shastri, L. Fong, and J. P. Allison. 2008. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: a prostate tumor antigen identified by CTLA-4 blockade. Proc. Natl. Acad. Sci. USA 105: 3509-3514.
38. Au-Yeung, B. B., J. Zikherman, J. L. Mueller, J. F. Ashouri, M. Matloubian, D. A. Cheng, Y. Chen, K. M. Shokat, and A. Weiss. 2014. A sharp T-cell antigen receptor signaling threshold for T-cell proliferation. Proc. Natl. Acad. Sci. USA 111: E3679-E3688.
39. Ahmed, R., and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272: 54-60.
40. Slifka, M. K., F. Rodriguez, and J. L. Whitton. 1999. Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells. Nature 401: 76-79.
41. Thompson, E. D., H. L. Enriquez, Y. X. Fu, and V. H. Engelhard. 2010. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207: 1791-1804.
42. Bansal-Pakala, P., B. S. Halteman, M. H. Cheng, and M. Croft. 2004. Costimulation of CD8 T cell responses by OX40. J. Immunol. 172: 4821-4825.
43. Kotani, A., T. Ishikawa, Y. Matsumura, T. Ichinohe, H. Ohno, T. Hori, and T. Uchiyama. 2001. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood 98: 3162-3164.
44. Klinger, M., J. K. Kim, S. A. Chmura, A. Barczak, D. J. Erle, and N. Killeen. 2009. Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J. Immunol. 182: 4581-4589.
45. Kaech, S. M., and R. Ahmed. 2001. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat. Immunol. 2: 415-422.
46. Murali-Krishna, K., and R. Ahmed. 2000. Cutting edge: naive T cells masquerading as memory cells. J. Immunol. 165: 1733-1737.
47. Mempel, T. R., S. E. Henrickson, and U. H. Von Andrian. 2004. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427: 154-159.
48. Song, A., X. Tang, K. M. Harms, and M. Croft. 2005. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J. Immunol. 175: 3534-3541.
49. Berd, D., H. C. Maguire, Jr., M. J. Mastrangelo, and G. Murphy. 1994. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol. Immunother. 39: 141-147.
50. Kinter, A. L., E. J. Godbout, J. P. McNally, I. Sereti, G. A. Roby, M. A. O'Shea, and A. S. Fauci. 2008. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181: 6738-6746.
51. Polanczyk, M. J., C. Hopke, A. A. Vandenbark, and H. Offner. 2006. Estrogenmediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J. Neurosci. Res. 84: 370-378.
52. Terawaki, S., S. Chikuma, S. Shibayama, T. Hayashi, T. Yoshida, T. Okazaki, and T. Honjo. 2011. IFN-A directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186: 2772-2779.
53. Gerner, M. Y., L. M. Heltemes-Harris, B. T. Fife, and M. F. Mescher. 2013. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J. Immunol. 191: 1011-1015.
54. Rekik, R., N. Belhadj Hmida, A. Ben Hmid, I. Zamali, N. Kammoun, and M. Ben Ahmed. 2015. PD-1 induction through TCR activation is partially regulated by endogenous TGF-b. Cell. Mol. Immunol. 12: 648-649.
55. Vanpouille-Box, C., J. M. Diamond, K. A. Pilones, J. Zavadil, J. S. Babb, S. C. Formenti, M. H. Barcellos-Hoff, and S. Demaria. 2015. TGFb is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75: 2232-2242.
56. Blattman, J. N., E. J. Wherry, S. J. Ha, R. G. van der Most, and R. Ahmed. 2009. Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J. Virol. 83: 4386-4394.
57. Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8: 765-772.
58. Tough, D. F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950.
59. Unutmaz, D., P. Pileri, and S. Abrignani. 1994. Antigen-independent activation of naive and memory resting T cells by a cytokine combination. J. Exp. Med. 180: 1159-1164.
60. Rogers, P. R., J. Song, I. Gramaglia, N. Killeen, and M. Croft. 2001. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15: 445-455.
61. Kalia, V., L. A. Penny, Y. Yuzefpolskiy, F. M. Baumann, and S. Sarkar. 2015. Quiescence of memory CD8(+) T cells is mediated by regulatory T cells through inhibitory receptor CTLA-4. Immunity 42: 1116-1129.
62. Simpson, T. R., F. Li, W. Montalvo-Ortiz, M. A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J. Y. Henry, H. Yagita, J. D. Wolchok, et al. 2013. Fcdependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210: 1695-1710.
63. Stritesky, G. L., Y. Xing, J. R. Erickson, L. A. Kalekar, X. Wang, D. L. Mueller, S. C. Jameson, and K. A. Hogquist. 2013. Murine thymic selection quantified using a unique method to capture deleted T cells. Proc. Natl. Acad. Sci. USA 110: 4679-4684.